KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
22. Oktober 2024 07:00 ET
|
KSQ
KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
08. Oktober 2024 07:00 ET
|
KSQ
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
24. September 2024 07:00 ET
|
KSQ
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
KSQ Therapeutics to Participate in Upcoming Investor Conferences
28. August 2024 07:00 ET
|
KSQ
KSQ Therapeutics to Participate in Upcoming Investor Conferences
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
12. Juni 2024 07:00 ET
|
KSQ
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered eTIL® Therapy
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
29. November 2023 07:00 ET
|
KSQ
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy